This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visist to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy
Versameb AG Announces Grant of First Patent in China for “Signal Peptide with Heterologous Protein”
news versamebPRESS RELEASE | Basel, Switzerland, March 20, 2025
Versameb AG (“Versameb”), a clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced the issuance of the Notice of Allowance of first Composition of Matter patent in China for its innovative signal peptide technology. This achievement represents a significant milestone in Versameb’s mission to advance RNA-based therapeutics and expand its intellectual property portfolio globally.
Versameb Announces Publication in Molecular Therapy – Nucleic Acids Journal Demonstrating the Potential of Engineered IGF-I mRNA as a Regenerative Therapeutic
news versamebPRESS RELEASE | Basel, Switzerland, December 12, 2023
Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced the publication of a scientific manuscript in the internationally recognized scientific journal, Molecular Therapy – Nucleic Acids.
Versameb AG Names Dr. Alexandre LeBeaut as Chair of the Board of Directors
news versamebPRESS RELEASE | Basel, Switzerland, December 5, 2023
Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that its Board of Directors has unanimously appointed of Dr. Alexandre LeBeaut, MD as Chairman of the Board, effective immediately. Dr. LeBeaut has over two decades of global R&D leadership experiences, successfully bringing multiple medicines to market in immunology, oncology, gastroenterology, cardio-metabolic and infectious diseases.
Versameb AG Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence
news versamebPRESS RELEASE | Basel, Switzerland, November 16, 2023
Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application of VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), for the treatment of stress urinary incontinence (SUI).
Versameb Strengthens its Board of Directors
news versamebPRESS RELEASE | Basel, Switzerland, July 10, 2023
Versameb AG (“Versameb”), transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut to its board of directors as it prepares to enter clinical development with lead candidate, VMB-100, an RNA-based therapy for the treatment of Stress Urinary Incontinence (SUI).